Privacy Policy
Signals Blog

Contributors

Categories

Up in the air

Flying a small plane may be easy to learn. Flying a jumbo jet safely, with hundreds of people’s lives in your hands, takes decades of training and testing. Cell and gene therapy today is a bit like a rookie pilot: it will still be some time of carefully monitored...

The Betrayal: turning cancer against itself

I honestly believe that we’re living in the most exciting time for cancer therapeutics. The past few years (dare I say decades, even?) have pushed the boundaries of cancer treatment from radiation and chemotherapy to the use of cancer-targeted antibodies, oncolytic...

Going in for the kill: NK cells enter the immunotherapy arena

Erika Siren lives in Vancouver, British Columbia where she is currently a Ph.D Candidate in the University of British Columbia’s Department of Chemistry. Under the supervision of Dr. Jayachandran Kizhakkedathu, Erika develops biomaterials that can be used to...

The long road to commercialization

Carmen Wong completed her PhD studies on creating viruses for cancer research. Since then, she has been working with inventors from universities, accelerators, and startup companies to commercialize their innovations. Carmen was a commercialization analyst with CCRM...

Right Turn: The ABCs of IP and CEO

For Canada to thrive, supporting and training our future work force and leaders is crucial. This can happen in a myriad of ways. For a group of Canadian organizations in the biotherapeutics field, this has taken the form of joining together to host training workshops...

Right Turn: CRISPR, at a theatre near you

Does it seem like CRISPR is everywhere these days? That’s because it is! The popular gene editing tool – Clustered Regularly Interspaced Short Palindromic Repeats – is significant for its ability to edit DNA at precise locations, making it possible to correct...